BioMarin Pharmaceutical (NASDAQ:BMRN) and Amicus Therapeutics (NASDAQ:FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction.
The total equity value of the transaction is approximately $4.8 billion.
The agreement has been unanimously approved by the Boards of Directors of both companies, and Amicus' Board of Directors has unanimously recommended that its stockholders vote to adopt the agreement.
The acquisition is expected to close in the second quarter of 2026, subject to regulatory clearances, approval by Amicus' stockholders, and other customary closing conditions.
This acquisition strengthens BioMarin’s position in the pharmaceutical industry and expands its portfolio in rare disease therapies, reinforcing its commitment to delivering life-changing treatments to patients.